Effective Adjunctive Use of Pergolide for Cognitive Impairment and Negative Symptoms in Schizophrenia

Suspended

• Conditions: Schizophrenia; Cognitive Impairments; Negative Symptoms

• Registration Number: NCT00197483
• Lead Sponsor: Hamamatsu University

Brief Summary

Dopamine has been closely associated with prefrontal function. The hypothesis that a lower dopaminergic activity is associated with negative symptoms and cognitive dysfunction observed in the patients of schizophrenia is of a heuristic value in guiding research in this area. This hypothesis led us to test whether pergolide, a D1/D2 agonist, could improve negative symptoms and cognitive impairments prevailing in most patients with schizophrenia. This double-blind placebo controlled study will investigate the remedial effect of pergolide on negative symptoms and cognitive impairments in schizophrenia.

Detailed Description

Not available

Study Timeline

• Study Start: 2003-03
• Status Verified: 2005-09
• Study First Submitted: 2005-09-13
• Study First Submitted QC: 2005-09-13
• Last Update Submitted: 2005-09-13
• Study First Posted: 2005-09-20
• Last Update Posted: 2005-09-20

Recruitment & Eligibility

• Status: SUSPENDED
• Sex: All
• Target Recruitment: 20

Inclusion Criteria

Patients

• Were age 18-50 years, met the DSM-IV criteria for schizophrenia
• Were treated with a stable dose of risperidone, raging 2 to 6mg, for more than 8 weeks
• Had a score ≥15 on negative subscale items in Positive and Negative Syndrome Scale (PANSS)
• Had a minimum period of symptom stability, defined as no more than 20% change on consecutive ratings on PANSS for at lease 4 weeks

Exclusion Criteria

• Had a history of medical condition or drug treatment that may have affected cognitive performance
• Had a history of other psychiatric disorders

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Trial Locations

Locations (1)

Hamamatsu University Hospital; 🇯🇵 Hamamatsu, Shizuoka, Japan